Clinical trial
Post Authorization Safety Study Assessing the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
NCT06714448 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Post Authorization Safety Study Assessing the Effectiveness of Risk Minimization Measures Related to Depakine® (Sodium Valproate) in Saudi Arabia
- Lead sponsor
- Sanofi
- Phase
- Observational
- Overall status
- Completed
- Start date
- April 29, 2025
- Completion date
- September 22, 2025
- Enrollment
- 455 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.